The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial
Abstract
AIMS A guided de-escalation of P2Y12 inhibitor treatment is considered as an alternative treatment strategy in ACS patients undergoing PCI. However, the safety and efficacy of this strategy may differ in diabetic vs. non-diabetic patients. The aim of this study was to compare the outcomes of platelet function testing (PFT) guided de-escalation of dual antiplatelet treatment (DAPT) in ACS patients with and without diabetes mellitus. METHODS AND RESULTS TROPICAL-ACS trial randomized 2610 biomarker-positive ACS patients 1:1 to either standard treatment with prasugrel for 12 months (control group) or to PFT guided DAPT de-escalation. The association and interaction of diabetes on clinical endpoints across treatment groups and on platelet reactivity was investigated. In diabetic patients (n=527, 20.2%), the overall event rates were high and the 1-year incidence of the primary endpoint (cardiovascular death, myocardial infarction, stroke or bleeding ≥ grade 2) did not differ between guided de-escalation and control group patients (12.5% vs. 10.8%; HR 1.17, 95% CI 0.71-1.93, p=0.55). In non-diabetic patients (n=2083, 79.8%), the 1-year incidence of the primary endpoint was lower in the guided de-escalation vs. control group (6.1% vs. 8.5%; HR 0.71, 95% CI 0.52-0.99, p=0.04, pint=0.10) Diabetic patients showed higher platelet reactivity levels in both control (=on prasugrel, p=0.01) and guided de-escalation group (=on-clopidogrel, p=0.005) patients. CONCLUSIONS Although diabetic stat…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“No evidence supports shortening or de-escalating DAPT post-ACS specifically in patients with diabetes”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [321]
In the citing paper
“since RCTs on shorter DAPT duration followed by ASA or a P2Y 12 inhibitor monotherapy are relatively small, often with non-inferiority design for efficacy, relatively low power, and wide noninferiority margins.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [321]
In the citing paper
“Of note, the TROPICAL-ACS (Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes) trial 'deescalating' P2Y 12 inhibition from prasugrel to clopidogrel after 2 weeks of DAPT based on platelet function testing showed an upper HR limit for MACE of 1.93 in the diabetes sub-group (HR 1.17; 95% CI, 0.71-1.93).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [321]
In the citing paper
“thus suggesting harm from de-escalation compared with standard recommended DAPT.321”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [321]
In the citing paper
“Moreover, CV death was significantly increased in sub-groups with diabetes vs. without diabetes in the 'de-escalating' arm (HR 2.42; 95% CI, 0.61-9.67;P int = 0.04)”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [321]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
Self-citationClinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Tantry, U. S., Bonello, L., Aradi, D., Price, M. J., Jeong, Y.-H., Angiolillo, D. J., Stone, G. W., Curzen, N., Geisler, T., ten Berg, J., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.101 · Cited by 910
Self-citationWiviott, S. D., Braunwald, E., Angiolillo, D. J., Meisel, S., Dalby, A. J., Verheugt, F. W. A., Goodman, S. G., Corbalan, R., Purdy, D. A., Murphy, S. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.791061 · Cited by 754
Diabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716
Sibbing, D., Aradi, D., Jacobshagen, C., Gross, L., Trenk, D., Geisler, T., Orban, M., Hadamitzky, M., Merkely, B., Kiss, R. G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32155-4 · Cited by 615
Self-citationAngiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Ramírez, C., Sabaté, M., Jimenez-Quevedo, P., Hernández, R., Moreno, R., Escaned, J., Alfonso, F., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2430 · Cited by 538
Cuisset, T., Deharo, P., Quilici, J., Johnson, T. W., Deffarges, S., Bassez, C., Bonnet, G., Fourcade, L., Mouret, J. P., Lambert, M., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx175 · Cited by 414
International Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies
Angiolillo, D. J., Rollini, F., Storey, R. F., Bhatt, D. L., James, S., Schneider, D. J., Sibbing, D., So, D. Y. F., Trenk, D., Alexopoulos, D., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.031164 · Cited by 397
Self-citation
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Antithrombotic therapy in diabetes: which, when, and for how long?
Ajjan, R., Kietsiriroje, N., Badimón, L., Vilahur, G., Gorog, D. A., Angiolillo, D. J., Russell, D., Rocca, B., & Storey, R. F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab128 · Cited by 74
Gorog, D. A., & Geisler, T. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1702920 · Cited by 24
Zheng, Y., Wu, T., Yang, Y., Hou, X., Chen, Y., Ma, X., Ma, Y., Zhang, J., & Xie, X. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab612 · Cited by 13
Wang, H., Cai, Z., Yin, D., Song, W., Feng, L., Gao, R.-L., Yang, Y., & Dou, K. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.586491 · Cited by 8
Metadata
- Authors
- Hein, R., Gross, L., Aradi, D., Rieber, J., Hadamitzky, M., Merkely, B., Huczek, Z., Ince, H., Hummel, A., Baylacher, M., Massberg, S., Trenk, D., & Sibbing, D.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- ORCID
- Venue
- EuroIntervention
- Publisher
- Europa Digital & Publishing
- Published
- 2019-08
- Volume
- 15
- Issue
- 6
- Pages
- e513-e521
- ISSN
- 1774-024X (ISSN-L)
- 1969-6213
- OpenAlex
- W2968073174
- Cited by
- 12
- References
- 26
- Citations by year
- 2025: 3 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 1
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- EuroIntervention (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- diabetes mellitus, antiplatelet therapy de-escalation, P2Y12 inhibitors, prasugrel, clopidogrel, platelet function testing, acute coronary syndrome, percutaneous coronary intervention, dual antiplatelet therapy, platelet reactivity, bleeding risk
- MeSH terms
- Prasugrel Hydrochloride, Diabetes Mellitus, Humans, Platelet Aggregation Inhibitors, Platelet Function Tests, Treatment Outcome, Acute Coronary Syndrome, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial. https://app.cochat.ai/papers/10.4244/eij-d-18-01077
- The paper
- Hein, R., Gross, L., Aradi, D., Rieber, J., Hadamitzky, M., Merkely, B., Huczek, Z., Ince, H., Hummel, A., Baylacher, M., Massberg, S., Trenk, D., & Sibbing, D. (2019). Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial. EuroIntervention. https://doi.org/10.4244/eij-d-18-01077
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.